[1]田 磊,赵昕锐,李洪超.我国肿瘤免疫治疗经济学评价研究现状与挑战[J].卫生经济研究,2021,38(1):35-39.
　TIAN Lei,ZHAO Xin-rui,LI Hong-chao.Research Status and Challenge of Economic Evaluation of Tumor Immunotherapy in China[J].Journal Press of Health Economics Research,2021,38(1):35-39.
点击复制

我国肿瘤免疫治疗经济学评价研究现状与挑战
分享到：

卫生经济研究[ISSN:1004-7778/CN:33-1056/F]

卷:
38
期数:
2021年1期
页码:
35-39
栏目:
经济学评价
出版日期:
2021-01-07

文章信息/Info

Title:
Research Status and Challenge of Economic Evaluation of Tumor Immunotherapy in China
作者:
田 磊1; 赵昕锐1; 李洪超1
1.中国药科大学国际医药商学院，药物经济学评价研究中心，江苏 南京 211198
Author(s):
TIAN Lei; ZHAO Xin-rui; LI Hong-chao
Center for Pharmacoeconomics and Outcomes Research,School of International Pharmaceutical Business, China Pharmaceutical University, Nanjing Jiangsu 211198,China
关键词:
肿瘤免疫治疗; 经济学评价; 价值评估
Keywords:
tumor immunotherapy;  economic evaluation;  value evaluation
分类号:
R19
文献标志码:
A
摘要:
随着肿瘤免疫治疗的快速发展，其经济学评价也在逐步推进。由于免疫疗法与传统治疗在作用机制、临床效果等方面均有较大差异，不同药物之间的药学特征和临床疗效也不同，因此在进行经济学评价时应做出相应的调整。以目前在我国上市的PD-1/PD-L1抑制剂为例，对国内现有药物经济学评价进行总结，分析肿瘤免疫疗法经济学评价面临的挑战，如临床数据不足、生存数据的模拟与外推尚需验证、生命质量数据来源缺失、分适应症评价的挑战，以及经济性与可负担性的矛盾等。
Abstract:
With the rapid development of tumor immunotherapy,its economic evaluation is also gradually advancing.There are great differences in action mechanism and clinical effect between immunotherapy and traditional therapy,and in the pharmaceutical characteristics and clinical efficacy of different drugs,so the economic evaluation should be made related adjustments.Taking the PD-1/PD-L1 inhibitors listed in China as an example, this paper summarizes the current pharmacoeconomic evaluation,and analyzes the challenges faced by the economic evaluation of tumor immunotherapy,such as lack of clinical data，simulation and extrapolation of survival data need to be verified,lack of the quality of life data source, challenge of indication evaluation,contradiction between economy and affordability,and so on.

参考文献/References:

[1] LIU Q, LUO X,PENG L, et al. Nivolumab Versus Docetaxel for Previously Treated Advanced Non-Small Cell Lung Cancer in China:A Cost-Effectiveness Analysis[J].Clin Drug Investig, 2020,40(2): 129-137.
[2] WENG X,HUANG X,LI H, et al.First-Line Treatment With Atezolizumab Plus Nab-Paclitaxel for Advanced Triple-Negative Breast Cancer:A Cost-Effectiveness Analysis[J].Am J Clin Oncol, 2020,43(5):340-348.
[3] LIU M,HAN S,ZHENG B,et al.Cost-Effectiveness Analysis Of Pembrolizumab In The Treatment Of Advanced Recurrent Metastatic Head And Neck Squamous Cell Carcinoma In China And The United States[J].Cancer Manag Res,2019,11:9483-9493.
[4] ZHOU K,LI Y,LIAO W,et al.Pembrolizumab alone or with chemotherapy for squamous cell carcinoma of the head and neck:A cost-effectiveness analysis from Chinese perspective[J]. Oral Oncol,2020,107:104754.
[5] LOONG H H,WONG C,LEUNG L,et al.Cost Effectiveness of PD-L1-Based Test-and-Treat Strategy with Pembrolizumab as the First-Line Treatment for Metastatic NSCLC in Hong Kong[J]. Pharmacoecon Open, 2019.
[6] LIAO W,HUANG J,HUTTON D,et al.Cost-effectiveness analysis of first-line pembrolizumab treatment for PD-L1 positive, non-small cell lung cancer in China[J].J Med Econ, 2019,22(4): 344-349.
[7] WAN N,ZHANG T T,HUA S H,et al.Cost-effectiveness analysis of pembrolizumab plus chemotherapy with PD-L1 test for the first-line treatment of NSCLC[J].Cancer Med,2020,9(5):1683-1693.
[8] HERBST R S,BAAS P, KIM D W,et al.Pembrolizumab versus docetaxel for previously treated, PD-L1-positive,advanced non-small-cell lung cancer (KEYNOTE-010):a randomised controlled trial[J].Lancet,2016,387(10027):1540-1550.
[9] RECK M,RODRIGUEZ-ABREU D,ROBINSON A G,et al.Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer[J].N Engl J Med,2016,375(19):1823-1833.
[10] COHEN E,SOULIERES D,Le TOURNEAU C,et al. Pembrolizumab versus methotrexate, docetaxel,or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040):a randomised, open-label, phase 3 study[J]. Lancet,2019,393(10167):156-167.
[11] MOK T,WU Y L,KUDABA I,et al.Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042):a randomised,open-label,controlled, phase 3 trial[J].Lancet,2019,393(10183):1819-1830.
[12] GANDHI L,RODRIGUEZ-ABREU D,GADGEEL S,et al.Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer[J].N Engl J Med,2018,378(22):2078-2092.
[13] WU Y,LU S,CHENG Y,et al.Nivolumab Versus Docetaxel in a Predominantly Chinese Patient Population With Previously Treated Advanced NSCLC: CheckMate 078 Randomized Phase III Clinical Trial[J].Journal of Thoracic Oncology,2019,14(5): 867-875.
[14] SCHMID P,ADAMS S,RUGO H S,et al.Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer[J].N Engl J Med,2018,379(22):2108-2121.
[15] GIBSON E,KOBLBAUER I,BEGUM N,et al.Modelling the Survival Outcomes of Immuno-Oncology Drugs in Economic Evaluations:A Systematic Approach to Data Analysis and Extrapolation[J].PharmacoEconomics,2017,35(12):1257-1270.
[16] OUWENS M,MUKHOPADHYAY P,ZHANG Y,et al.Estimating Lifetime Benefits Associated with Immuno-Oncology Therapies: Challenges and Approaches for Overall Survival Extrapolations[J].Pharmacoeconomics,2019,37(9):1129-1138.
[17] PENNINGTON M,GRIEVE R, der MEULEN J V,et al.Value of External Data in the Extrapolation of Survival Data:A Study Using the NJR Data Set[J].Value in Health,2018,21(7):822-829.
[18] BETH WOODS E S S P.NICE DSU TECHNICAL SUPPORT DOCUMENT 19：PARTITIONED SURVIVAL ANALYSIS FOR DECISION MODELLING IN HEALTH CARE:A CRITICAL REVIEW[R].2017.
[19] BULLEMENT A,LATIMER N R,BELL GORROD H. Survival Extrapolation in Cancer Immunotherapy:A Validation-Based Case Study[J].Value in Health, 2019,22(3):276-283.
[20] TANG WX S R S Y.COST-EFFECTIVENESS OF PEMBROLIZUMAB COMPARED TO CHEMOTHERAPY AS A TREATMENT FORPATIENTS WITH PREVIOUSLY TREATED ADVANCED MELANOMA IN CHINA[J].Value in Health, 2019,19(10): s15.
[21] HU S,FAN L,TANG Z,et al.PCN90 AN ECONOMIC EVALUATION OF NIVOLUMAB FOR THE TREATMENT OF ADVANCED NON-SMALL CELL LUNG CANCER (ANSCLC) AFTER PRIOR CHEMOTHERAPY IN CHINA[J].Value in Health,2019,22:S72.
[22] SHI Y,SU H, SONG Y,et al.Safety and activity of sintilimab in patients with relapsed or refractory classical Hodgkin lymphoma (ORIENT-1):a multicentre, single-arm,phase 2 trial[J].The Lancet Haematology,2019,6(1): e12-e19.
[23] SONG Y,GAO Q,ZHANG H,et al.Treatment of relapsed or refractory classical Hodgkin lymphoma with the anti-PD-1, tislelizumab:results of a phase 2,ingle-arm,multicenter study[J]. Leukemia,2020,34(2):533-542.
[24] NIE J,WANG C,LIU Y,et al.Addition of Low-Dose Decitabine to Anti PD-1 Antibody Camrelizumab in Relapsed/Refractory Classical Hodgkin Lymphoma[J].American Society of Clinical Oncology,2019,37(17):1479-1489.
[25] 王秀蓓，王海芳,钮美娥,等.癌症患者报告结局的研究进展[J]. 中国护理管理,2018,18（3）:423-427.
[26] TARTARI F,SANTONI M,BURATTINI L,et al.Economic sustainability of anti-PD-1 agents nivolumab and pembrolizumab in cancer patients:Recent insights and future challenges[J].Cancer Treatment Reviews,2016,48:20-24.
[27] HUANG M,LOU Y,PELLISSIER J,et al.Cost Effectiveness of Pembrolizumab vs.Standard-of-Care Chemotherapy as First-Line Treatment for Metastatic NSCLC that Expresses High Levels of PD-L1 in the United States[J].PharmacoEconomics, 2017,35(8):831-844.
[28] WANG J,CHMIELOWSKI B,PELLISSIER J,et al.Cost-Effectiveness of Pembrolizumab Versus Ipilimumab in Ipilimumab-Na?觙ve Patients with Advanced Melanoma in the United States[J].Journal of managed care & specialty pharmacy,2017,23(2):184.
[29] BERNARD-ARNOUX F,LAMURE M,DUCRAY F,et al.The cost-effectiveness of tumor-treating fields therapy in patients with newly diagnosed glioblastoma[J].Neuro-Oncology,2016,18(8): 1129-1136.
[30] RASCATI K L.The $64,000 question—What is a quality-adjusted life-year worth?[J].Clinical Therapeutics,2006,28(7):1042-1043.
[31] CARRERA P,IJZERMAN M J.Are current ICER thresholds outdated? Valuing medicines in the era of personalized healthcare[J].Expert Review of Pharmacoeconomics & Outcomes Research, 2016,16(4):435-437.
[32] DA VEIGA C R P,DA VEIGA C P DRUMMOND-LAGE A P. Concern over cost of and access to cancer treatments: A meta-narrative review of nivolumab and pembrolizumab studies[J]. Critical Reviews in Oncology/Hematology,2018,129:133-145.

相似文献/References:

[1]于保荣,许 晴,刘 卓,等.新发传染病经济负担的方法学研究[J].卫生经济研究,2017,(07):25.
[2]朱 宏,黄鸿燕,郑胄斌,等.日间手术的经济学评价研究综述[J].卫生经济研究,2021,38(9):25.
　ZHU Hong,ZHENG Zhou-bin,HUANG Hong-yan,et al.Overview on Day Operation Economic Evaluation Research[J].Journal Press of Health Economics Research,2021,38(1):25.
[3]卢钰琼,代展菁,路 云,等.健康状态效用值测量研究报告规范及对比研究[J].卫生经济研究,2022,39(7):68.
　LU Yuqiong,DAI Zhanjing,LU Yun,et al.Reporting Guidelines for and Comparative Study of Health State Utility Values Estimation[J].Journal Press of Health Economics Research,2022,39(1):68.
[4]于保荣,孔维政,王 庆.普惠险药品准入机制与评估体系研究[J].卫生经济研究,2022,39(8):1.
　YU Baorong,KONG Weizheng,WANG Qing.Research on Access Mechanism and Evaluation System of Inclusive Insurance Drugs[J].Journal Press of Health Economics Research,2022,39(1):1.
[5]汤雅倩,赵明烨,唐文熙.信迪利单抗对比卡瑞利珠单抗一线治疗 晚期非鳞状非小细胞肺癌的经济学评价[J].卫生经济研究,2023,40(2):34.
　TANG Yaqian,ZHAO Mingye,TANG Wenxi.Pharmacoeconomic Evaluation of Sintilimab Versus Camrelizumab in the First-Line Treatment of Patients with Non-Squamous Advanced Non-Small Cell Lung Cancer in China[J].Journal Press of Health Economics Research,2023,40(1):34.
[6]湛浩然,胡玉瑶,孙雨馨,等.分布式成本效果评价方法及研究现状[J].卫生经济研究,2023,40(9):85.
　ZHAN Haoran,HU Yuyao,SUN Yuxin,et al.Introduction and Application Status of Distributional Cost-effectiveness Analysis[J].Journal Press of Health Economics Research,2023,40(1):85.

更新日期/Last Update: 2021-01-07